TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.53
+6.76%0
Insider buys (3m)
8
Insider sells (3m)
-$2.2M
Net value (3m)
-16.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 5, 2026 | Crystal Adam · officer: President, R&D | Sale | 600 | $25 |
| Oct 5, 2026 | Crystal Adam · officer: President, R&D | M-Exempt | 27,000 | $5.20 |
| Oct 5, 2026 | Crystal Adam · officer: President, R&D | Sale | 26,400 | $24 |
| Sep 24, 2026 | Newcomb Jessica · officer: Principal Accounting Officer | Sale | 700 | $23 |
| Sep 24, 2026 | Newcomb Jessica · officer: Principal Accounting Officer | Sale | 5,100 | $24 |
| Sep 24, 2026 | Newcomb Jessica · officer: Principal Accounting Officer | Sale | 2,400 | $25 |
| Sep 3, 2026 | Crystal Adam · officer: President, R&D | Sale | 27,000 | $22 |
| Sep 3, 2026 | Crystal Adam · officer: President, R&D | M-Exempt | 27,000 | $5.20 |
| Aug 5, 2026 | Crystal Adam · officer: President, R&D | Sale | 21,733 | $27 |
| Aug 5, 2026 | Crystal Adam · officer: President, R&D | M-Exempt | 27,000 | $5.20 |
| Aug 5, 2026 | Crystal Adam · officer: President, R&D | Sale | 5,267 | $27 |
| Jul 2, 2026 | Crystal Adam · officer: President, R&D | M-Exempt | 27,000 | $5.20 |
| Jul 2, 2026 | Crystal Adam · officer: President, R&D | Sale | 19,629 | $29 |
| Jul 2, 2026 | Crystal Adam · officer: President, R&D | Sale | 7,371 | $30 |
| Jun 23, 2026 | Azelby Robert · director | A-Award | 35,910 | $28 |
| Jun 23, 2026 | Azelby Robert · director | A-Award | 5,740 | $0.00 |
| Jun 8, 2026 | Lee Sung · director | A-Award | 3,570 | $20 |
| Jun 8, 2026 | Ketchum John B · director | A-Award | 4,000 | $0.00 |
| Jun 8, 2026 | Ketchum John B · director | A-Award | 25,000 | $20 |
| Jun 8, 2026 | Calhoun Lesley Ann · director | A-Award | 4,000 | $0.00 |
| Jun 8, 2026 | Calhoun Lesley Ann · director | A-Award | 25,000 | $20 |
| Jun 8, 2026 | Rothenberg Mace · director | A-Award | 4,000 | $0.00 |
| Jun 8, 2026 | Rothenberg Mace · director | A-Award | 25,000 | $20 |
| Jun 8, 2026 | Lee Sung · director | A-Award | 570 | $0.00 |
| Jun 3, 2026 | Crystal Adam · officer: President, R&D | Sale | 6,140 | $22 |
| Jun 3, 2026 | Crystal Adam · officer: President, R&D | M-Exempt | 27,000 | $5.20 |
| Jun 3, 2026 | Crystal Adam · officer: President, R&D | Sale | 20,860 | $23 |
| May 5, 2026 | Crystal Adam · officer: President, R&D | Sale | 25,900 | $21 |
| May 5, 2026 | Gall Matthew · officer: Chief Financial Officer | A-Award | 40,000 | $0.00 |
| May 5, 2026 | Gall Matthew · officer: Chief Financial Officer | A-Award | 240,000 | $21 |
Institutional positioning
13F filings over the trailing two quarters
New 134Increased 159Reduced 115Sold out 31
| Filer | Action | Shares | Filed |
|---|---|---|---|
| RTW INVESTMENTS, LP | Increased | 13,900,620 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Increased | 13,300,620 | May 15, 2026 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | Increased | 12,809,485 | May 15, 2026 |
| BlackRock, Inc. | Increased | 12,438,444 | Aug 7, 2026 |
| FMR LLC | Increased | 12,333,339 | Aug 13, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Increased | 12,277,000 | Aug 14, 2026 |
| BOXER CAPITAL MANAGEMENT, LLC | Unchanged | 10,876,219 | May 15, 2026 |
| Boxer Capital Management, LLC | Unchanged | 10,876,219 | Aug 14, 2026 |
| TCG CROSSOVER MANAGEMENT, LLC | Reduced | 10,531,071 | May 15, 2026 |
| GOLDMAN SACHS GROUP INC | Increased | 9,980,620 | Aug 14, 2026 |
| FMR LLC | Increased | 9,905,919 | May 15, 2026 |
| FARALLON CAPITAL MANAGEMENT LLC | Reduced | 9,097,411 | May 15, 2026 |
| TCG Crossover Management, LLC | Reduced | 9,081,201 | Aug 14, 2026 |
| BLACKROCK, INC. | Increased | 8,748,045 | May 13, 2026 |
| WOODLINE PARTNERS LP | Reduced | 8,000,013 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 5, 2026